NCT06662123View on ClinicalTrials.gov

Pharmacokinetic and Safety Study of Subcutaneous and Intravenous Anifrolumab Delivered in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

October 21, 2024

Primary Completion Date

January 10, 2025

Study Completion Date

January 10, 2025

Conditions

Healthy Volunteers

Interventions

DRUG

Anifrolumab

Participants will receive a single SC or IV dose of anifrolumab at day 1

Trial Locations (1)

430022

Research Site, Wuhan

Sponsors

Lead Sponsor

All Listed Sponsors

lead

AstraZeneca

INDUSTRY